GlassScriptPhysician profile
Adean Kingston
NPI 1427190388
$141,164.21
in general payments reported to CMS, 2019-2025
43 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $13K · 2022: $27K · 2023: $36K · 2024: $21K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $11K · Travel and Lodging: $1,221 · Consulting Fee: $350 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,550.00 |
| Food and Beverage | $11,015.64 |
| Travel and Lodging | $1,220.93 |
| Consulting Fee | $350.00 |
| Education | $101.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $120,003.29 | 2019-2025 | Aklief, Epsolay, Twyneo |
| Journey Medical Corporation | $3,550.18 | 2019-2025 | |
| Abbvie INC. | $1,880.88 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,564.81 | 2019-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $1,371.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,343.79 | 2020-2025 | Dupixent |
| Ucb, INC. | $939.75 | 2019-2025 | Bimzelx |
| Almirall LLC | $843.86 | 2019-2025 | Klisyri, Seysara |
| Amgen INC. | $795.65 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $752.62 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Vyne Pharmaceuticals INC. | $690.42 | 2020-2021 | |
| Medimetriks Pharmaceuticals, INC. | $680.82 | 2019-2025 | Neo-Synalar, Clindacin Etz |
| Pfizer INC. | $602.44 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $597.30 | 2019-2025 | |
| Janssen Biotech, INC. | $595.36 | 2021-2024 | Tremfya, Stelara, Remicade |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adean Kingston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.